Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
about
Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brainNeuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin.DNA methylation status of nuclear-encoded mitochondrial genes underlies the tissue-dependent mitochondrial functionsInhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.Transglutaminase 2 is secreted from smooth muscle cells by transamidation-dependent microparticle formation.Proteins with Intrinsically Disordered Domains Are Preferentially Recruited to Polyglutamine Aggregates.Tissue transglutaminase crosslinks ataxin-1: possible role in SCA1 pathogenesis.γ-Glutamylamines and neurodegenerative diseasesTransglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiationTransglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria.Tissue-type transglutaminase and the effects of cystamine on intracerebral hemorrhage-induced brain edema and neurological deficits.Transglutaminase activation in neurodegenerative diseases.Transglutaminases and neurodegeneration.Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.Evidences for a role of protein cross-links in transglutaminase-related disease.Transglutaminase 2 and neuroinflammation.Receptor-stimulated transamidation induces activation of Rac1 and Cdc42 and the regulation of dendritic spines.Transglutaminase-catalyzed transamidation: a novel mechanism for Rac1 activation by 5-hydroxytryptamine2A receptor stimulationDéjà vu with a twist: transglutaminases in bioenergetics and transcriptional dysfunction in Huntington's disease.Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease.Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.Towards an Understanding of Energy Impairment in Huntington's Disease Brain.
P2860
Q28580981-853B6354-C71D-4A8F-AFF8-6CD2B639FB0FQ33588238-868175D5-E276-44BA-968A-C15BA9B94B67Q33665573-B6E87A01-4F25-427B-A417-924FE5D85B2CQ34743269-A0830118-72C1-4D08-8BA3-8E29B9EC59BEQ35697155-ED027E85-D648-4285-B22F-051FD343E5BEQ35758594-35C6A160-6EB6-41A8-B566-FF20EC00D3D6Q36227615-B4950C23-1536-4FC3-90EB-99E6EDD46749Q36377238-1FB1A64F-2A8D-4AB3-9225-CFC2B5839F6CQ36711191-820F3488-BF90-4DBD-9D00-BBAF785884DDQ37001587-317DA56C-13FC-4D56-9971-3137B27AE655Q37195530-CC5B43E8-A786-4281-953C-567F01654B63Q37352964-3BC53FEA-4113-42F6-B6E9-837B2F40F933Q37365083-FE42F5F2-E082-44AD-AFAB-31EB416CD7E5Q37866383-55EA6D41-90D8-4D02-9093-5947F87F60BEQ37907975-F1DF046A-C0BB-402B-80E0-07221FB56273Q38268274-CD5AF55C-FAB6-44AB-A4AB-81A1BF969475Q38717959-4AF6903E-1A6A-4C9C-8BA2-27239F86C834Q39993532-8420474F-CCDF-4FB3-8D1F-750DACC93D6FQ42204907-3C52CDBB-ECE4-4FED-8270-51E4B1477BCBQ45297332-F69570DF-8022-4336-B745-C5A8D1C25D91Q45298533-8C5FC700-5D56-43D3-90DD-BC6EC3C75590Q47442924-8F33598E-4F82-4C35-8C4C-A836BC7B0562
P2860
Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
@en
type
label
Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
@en
prefLabel
Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
@en
P2093
P2860
P356
P1476
Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
@en
P2093
Gina M Zainelli
Nichole L Dudek
Soo-Youl Kim
P2860
P356
10.1093/JNEN/64.1.58
P577
2005-01-01T00:00:00Z